Jian Gu

List of Publications by Year in Descending Order

190 papers	8,877 citations	53 h-index	86 g-index
217 ext. papers	9,844 ext. citations	7.1 avg, IF	5.44 L-index

#	Paper	IF	Citations
190	A whole-exome case-control association study to characterize the contribution of rare coding variation to pancreatic cancer risk.. *Human Genetics and Genomics Advances*, **2022**, 3, 100078	0.8	
189	Prognostic significance of circulating insulin growth-like factor 1 and insulin growth-like factor binding protein 3 in renal cell carcinoma patients.. *American Journal of Cancer Research*, **2022**, 12, 852-860	4.4	
188	Genome-wide DNA methylation profiling of leukocytes identifies CpG methylation signatures of aggressive prostate cancer. *American Journal of Cancer Research*, **2021**, 11, 968-978	4.4	0
187	Genetically predicted high circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 increase the risks of soft tissue sarcoma. *American Journal of Cancer Research*, **2021**, 11, 3980-3989	4.4	
186	High circulating insulin-like growth factor-1 reduces the risk of renal cell carcinoma: a Mendelian randomization study. *Carcinogenesis*, **2021**, 42, 826-830	4.6	2
185	Integration of circulating tumor cell and neutrophil-lymphocyte ratio to identify high-risk metastatic castration-resistant prostate cancer patients. *BMC Cancer*, **2021**, 21, 655	4.8	1
184	Associations of genetically predicted circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with bladder cancer risk. *Molecular Carcinogenesis*, **2021**, 60, 726-733	5	2
183	Leukocyte Telomere Length and Bladder Cancer Risk: A Large Case-Control Study and Mendelian Randomization Analysis. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 203-209	4	3
182	Improved Prognostic Stratification Using Circulating Tumor Cell Clusters in Patients with Metastatic Castration-Resistant Prostate Cancer. *Cancers*, **2021**, 13,	6.6	5
181	Long Leukocyte Telomere Length Is Associated with Increased Risks of Soft Tissue Sarcoma: A Mendelian Randomization Study. *Cancers*, **2020**, 12,	6.6	6
180	Genetic variants in epithelial-mesenchymal transition genes as predictors of clinical outcomes in localized prostate cancer. *Carcinogenesis*, **2020**, 41, 1057-1064	4.6	
179	Leukocyte telomere length is associated with aggressive prostate cancer in localized African American prostate cancer patients. *Carcinogenesis*, **2020**, 41, 1213-1218	4.6	1
178	Leukocyte telomere length is associated with aggressive prostate cancer in localized prostate cancer patients. *EBioMedicine*, **2020**, 52, 102616	8.8	5
177	Elevated systemic inflammatory responses, factors associated with physical and mental quality of life, and prognosis of hepatocellular carcinoma. *Aging*, **2020**, 12, 4357-4370	5.6	3
176	Prognostic value of leukocyte telomere length in renal cell carcinoma patients. *American Journal of Cancer Research*, **2020**, 10, 3428-3439	4.4	0
175	Mitochondrial DNA copy number in peripheral blood leukocytes is associated with biochemical recurrence in prostate cancer patients in African Americans. *Carcinogenesis*, **2020**, 41, 267-273	4.6	5
174	Methylation of global DNA repeat LINE-1 and subtelomeric DNA repeats D4Z4 in leukocytes is associated with biochemical recurrence in African American prostate cancer patients. *Carcinogenesis*, **2019**,	4.6	3

173	Genetic variants in the nucleotide excision repair genes are associated with the risk of developing endometriosis. *Biology of Reproduction*, **2019**, 101, 928-937	3.9	5
172	Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort. *OncoImmunology*, **2019**, 8, e1483303	7.2	6
171	Reply to TMosaic loss of chromosome Y in leukocytes mattersT *Nature Genetics*, **2019**, 51, 7-9	36.3	6
170	The somatic mutation landscape of premalignant colorectal adenoma. *Gut*, **2018**, 67, 1299-1305	19.2	33
169	Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. *Clinical Pharmacology and Therapeutics*, **2018**, 103, 1061-1073	6.1	28
168	Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy. *Carcinogenesis*, **2017**, 38, 419-424	4.6	7
167	Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. *Oncology Letters*, **2017**, 13, 1949-1957	2.6	12
166	MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity. *British Journal of Cancer*, **2017**, 116, 77-84	8.7	30
165	Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma. *Cancer*, **2017**, 123, 3617-3627	6.4	17
164	High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis. *OncoImmunology*, **2017**, 6, e1265719	7.2	13
163	Energy stress-induced lncRNA FILNC1 represses c-Myc-mediated energy metabolism and inhibits renal tumor development. *Nature Communications*, **2017**, 8, 783	17.4	120
162	Polymorphisms in genes related to epithelial-mesenchymal transition and risk of non-small cell lung cancer. *Carcinogenesis*, **2017**, 38, 1029-1035	4.6	17
161	A miR-SNP biomarker linked to an increased lung cancer survival by miRNA-mediated down-regulation of FZD4 expression and Wnt signaling. *Scientific Reports*, **2017**, 7, 9029	4.9	12
160	Methylation of subtelomeric repeat D4Z4 in peripheral blood leukocytes is associated with biochemical recurrence in localized prostate cancer patients. *Carcinogenesis*, **2017**, 38, 821-826	4.6	5
159	Genetic variants in telomere-maintenance genes are associated with ovarian cancer risk and outcome. *Journal of Cellular and Molecular Medicine*, **2017**, 21, 510-518	5.6	6
158	Social-demographics, health behaviors, and telomere length in the Mexican American Mano a Mano Cohort. *Oncotarget*, **2017**, 8, 96553-96567	3.3	11
157	LINE-1 methylation in peripheral blood leukocytes and clinical characteristics and prognosis of prostate cancer patients. *Oncotarget*, **2017**, 8, 94020-94027	3.3	6
156	Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance. *Carcinogenesis*, **2016**, 37, 965-971	4.6	4

155	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. *Nature Communications*, **2016**, 7, 10933	17.4	70
154	Personalized Risk Assessment in Never, Light, and Heavy Smokers in a prospective cohort in Taiwan. *Scientific Reports*, **2016**, 6, 36482	4.9	21
153	Lower mitochondrial DNA copy number in peripheral blood leukocytes increases the risk of endometrial cancer. *Molecular Carcinogenesis*, **2016**, 55, 1111-7	5	11
152	Severe obesity prior to diagnosis limits survival in colorectal cancer patients evaluated at a large cancer centre. *British Journal of Cancer*, **2016**, 114, 103-9	8.7	25
151	Genomic DNA Hypomethylation and Risk of Renal Cell Carcinoma: A Case-Control Study. *Clinical Cancer Research*, **2016**, 22, 2074-82	12.9	18
150	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. *Human Molecular Genetics*, **2016**, 25, 1663-76	5.6	39
149	Cohort Profile: The MD Anderson Cancer Patients and Survivors Cohort (MDA-CPSC). *International Journal of Epidemiology*, **2016**, 45, 713-713f	7.8	10
148	Pathway analysis of bladder cancer genome-wide association study identifies novel pathways involved in bladder cancer development. *Genes and Cancer*, **2016**, 7, 229-239	2.9	11
147	Heritability of prostate cancer: a tale of rare variants and common single nucleotide polymorphisms. *Annals of Translational Medicine*, **2016**, 4, 206	3.2	10
146	Genetic variations in apoptosis pathway and the risk of ovarian cancer. *Oncotarget*, **2016**, 7, 56737-56745	5.3	1
145	Mosaic loss of chromosome Y is associated with common variation near TCL1A. *Nature Genetics*, **2016**, 48, 563-8	36.3	87
144	Biomarkers for Assessing Risk of Cancer **2015**, 317-330.e3		
143	Depressive symptoms and short telomere length are associated with increased mortality in bladder cancer patients. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 336-43	4	31
142	Leukocyte mitochondrial DNA content: a novel biomarker associated with prognosis and therapeutic outcome in colorectal cancer. *Carcinogenesis*, **2015**, 36, 543-52	4.6	19
141	The ability of bilirubin in identifying smokers with higher risk of lung cancer: a large cohort study in conjunction with global metabolomic profiling. *Clinical Cancer Research*, **2015**, 21, 193-200	12.9	36
140	Association of leukocyte telomere length in peripheral blood leukocytes with endometrial cancer risk in Caucasian Americans. *Carcinogenesis*, **2015**, 36, 1327-32	4.6	12
139	Mitochondrial DNA copy number in peripheral blood leukocytes and the risk of clear cell renal cell carcinoma. *Carcinogenesis*, **2015**, 36, 249-55	4.6	21
138	Prognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with non-metastatic breast cancer. *Carcinogenesis*, **2015**, 36, 243-8	4.6	83

137	Genetic variations in base excision repair pathway and risk of bladder cancer: a case-control study in the United States. *Molecular Carcinogenesis*, **2015**, 54, 50-7	5	9
136	Epigenetic analysis of microRNA genes in tumors from surgically resected lung cancer patients and association with survival. *Molecular Carcinogenesis*, **2015**, 54 Suppl 1, E45-51	5	11
135	Leukocyte Telomere Length and Cancer Risk: A Dynamic Problem. *EBioMedicine*, **2015**, 2, 493-4	8.8	4
134	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. *Journal of the National Cancer Institute*, **2015**, 107, djv279	9.7	107
133	Telomere length and recurrence risk after curative resection in patients with early-stage non-small-cell lung cancer: a prospective cohort study. *Journal of Thoracic Oncology*, **2015**, 10, 302-8	8.9	12
132	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. *Nature Communications*, **2015**, 6, 5751	17.4	44
131	Identification of Serum Markers of Esophageal Adenocarcinoma by Global and Targeted Metabolic Profiling. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1730-1737.e9	6.9	25
130	Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. *Oncotarget*, **2015**, 6, 41988-96	3.3	20
129	Genome-wide association study identifies multiple loci associated with bladder cancer risk. *Human Molecular Genetics*, **2014**, 23, 1387-98	5.6	101
128	Telomere length in peripheral blood leukocytes and lung cancer risk: a large case-control study in Caucasians. *Cancer Research*, **2014**, 74, 2476-86	10.1	67
127	The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients. *Clinical Cancer Research*, **2014**, 20, 5133-5139	12.9	25
126	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. *Nature Genetics*, **2014**, 46, 1233-8	36.3	108
125	Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. *American Journal of Human Genetics*, **2014**, 95, 462-71	11	74
124	Increased leukocyte mitochondrial DNA copy number is associated with oral premalignant lesions: an epidemiology study. *Carcinogenesis*, **2014**, 35, 1760-4	4.6	15
123	Genome-wide association study identifies variants in casein kinase II (CSNK2A2) to be associated with leukocyte telomere length in a Punjabi Sikh diabetic cohort. *Circulation: Cardiovascular Genetics*, **2014**, 7, 287-95		36
122	Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. *Nature Genetics*, **2014**, 46, 736-41	36.3	228
121	Genetic variants of the Wnt signaling pathway as predictors of recurrence and survival in early-stage non-small cell lung cancer patients. *Carcinogenesis*, **2014**, 35, 1284-91	4.6	19
120	Genetic and intermediate phenotypic susceptibility markers of gastric cancer in Hispanic Americans: a case-control study. *Cancer*, **2014**, 120, 3040-8	6.4	32

119	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. *Human Molecular Genetics*, **2014**, 23, 6616-33	5.6	77
118	Leukocyte telomere length and risk of secondary primary tumors in long-term breast cancer survivors.. *Journal of Clinical Oncology*, **2014**, 32, 9599-9599	2.2	
117	Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. *Cancer Research*, **2013**, 73, 4801-9	10.1	78
116	Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. *Carcinogenesis*, **2013**, 34, 2750-6	4.6	35
115	Long telomeres in peripheral blood leukocytes are associated with an increased risk of soft tissue sarcoma. *Cancer*, **2013**, 119, 1885-91	6.4	34
114	Ionizing radiation-induced γH2AX activity in whole blood culture and the risk of lung cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 443-51	4	14
113	Association of mitochondrial DNA copy number in peripheral blood leukocytes with risk of esophageal adenocarcinoma. *Carcinogenesis*, **2013**, 34, 2521-4	4.6	34
112	Risk assessment of esophageal adenocarcinoma using γH2AX assay. *Cancer Epidemiology Biomarkers and Prevention*, **2013**, 22, 1797-804	4	10
111	Reduced mitochondrial DNA copy number in peripheral blood leukocytes increases the risk of soft tissue sarcoma. *Carcinogenesis*, **2013**, 34, 1039-43	4.6	33
110	Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma. *Cancer*, **2013**, 119, 4277-83	6.4	27
109	Re: short telomere length, cancer survival, and cancer risk in 47 102 individuals. *Journal of the National Cancer Institute*, **2013**, 105, 1157	9.7	12
108	MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. *Cancer Prevention Research*, **2013**, 6, 196-205	3.2	77
107	MicroRNA in the pathogenesis and prognosis of esophageal cancer. *Current Pharmaceutical Design*, **2013**, 19, 1292-300	3.3	78
106	Comprehensive pathway-based interrogation of genetic variations in the nucleotide excision DNA repair pathway and risk of bladder cancer. *Cancer*, **2012**, 118, 205-15	6.4	12
105	GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. *Carcinogenesis*, **2012**, 33, 1327-31	4.6	39
104	Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study. *Clinical Cancer Research*, **2012**, 18, 5983-91	12.9	11
103	Germline prognostic markers for urinary bladder cancer: obstacles and opportunities. *Urologic Oncology: Seminars and Original Investigations*, **2012**, 30, 524-32	2.8	19
102	HSD3B and gene-gene interactions in a pathway-based analysis of genetic susceptibility to bladder cancer. *PLoS ONE*, **2012**, 7, e51301	3.7	14

101	A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. *Human Molecular Genetics*, **2012**, 21, 456-62	5.6	74
100	Association of Aurora-A (STK15) kinase polymorphisms with clinical outcome of esophageal cancer treated with preoperative chemoradiation. *Cancer*, **2012**, 118, 4346-53	6.4	21
99	Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. *Cancer*, **2012**, 118, 6188-98	6.4	10
98	Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. *Clinical Cancer Research*, **2012**, 18, 3982-91	12.9	63
97	Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk. *Carcinogenesis*, **2012**, 33, 1699-706	4.6	20
96	Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. *Carcinogenesis*, **2012**, 33, 841-7	4.6	4
95	Genetic variants in telomere-maintenance genes and bladder cancer risk. *PLoS ONE*, **2012**, 7, e30665	3.7	15
94	PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy. *Lung Cancer*, **2011**, 71, 82-8	5.9	51
93	Genetic susceptibility to bladder cancer risk and outcome. *Personalized Medicine*, **2011**, 8, 365-374	2.2	35
92	Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer. *PLoS ONE*, **2011**, 6, e21120	3.7	18
91	Global assessment of genetic variation influencing response to retinoid chemoprevention in head and neck cancer patients. *Cancer Prevention Research*, **2011**, 4, 185-93	3.2	34
90	MicroRNAs in Esophageal Cancer **2011**, 201-221		2
89	A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. *Cancer Prevention Research*, **2011**, 4, 514-21	3.2	60
88	A genetic variant near the PMAIP1/Noxa gene is associated with increased bleomycin sensitivity. *Human Molecular Genetics*, **2011**, 20, 820-6	5.6	10
87	Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer. *Carcinogenesis*, **2011**, 32, 1050-6	4.6	30
86	Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy. *Journal of the National Cancer Institute*, **2011**, 103, 817-25	9.7	73
85	Prospective analysis of DNA damage and repair markers of lung cancer risk from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Carcinogenesis*, **2011**, 32, 69-73	4.6	22
84	A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. *Human Molecular Genetics*, **2011**, 20, 4282-9	5.6	82

83	Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer. *Carcinogenesis*, **2011**, 32, 1867-71	4.6	10
82	Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma. *Oncogene*, **2010**, 29, 5724-8	9.2	177
81	Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. *PLoS ONE*, **2010**, 5, e12402	3.7	75
80	Genome-wide catalogue of chromosomal aberrations in barrett‡s esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. *Cancer Prevention Research*, **2010**, 3, 1176-86	3.2	67
79	Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients. *Carcinogenesis*, **2010**, 31, 1387-91	4.6	52
78	Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancer. *Cancer Prevention Research*, **2010**, 3, 1235-45	3.2	42
77	Prostate stem cell antigen: a Jekyll and Hyde molecule?. *Clinical Cancer Research*, **2010**, 16, 3533-8	12.9	126
76	Genetic variants in MicroRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival, and treatment response. *Cancer Research*, **2010**, 70, 9765-76	10.1	105
75	Pharmacogenetics of Lung Cancer **2010**, 87-106		
74	Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. *Carcinogenesis*, **2009**, 30, 2047-52	4.6	70
73	Constitutive short telomere length of chromosome 17p and 12q but not 11q and 2p is associated with an increased risk for esophageal cancer. *Cancer Prevention Research*, **2009**, 2, 459-65	3.2	61
72	Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on bladder cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 2090-7	4	38
71	Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. *Cancer Prevention Research*, **2009**, 2, 617-24	3.2	52
70	Role of inflammation gene polymorphisms on pain severity in lung cancer patients. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 2636-42	4	50
69	MicroRNA expression signatures in Barrett‡s esophagus and esophageal adenocarcinoma. *Clinical Cancer Research*, **2009**, 15, 5744-52	12.9	110
68	Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. *International Journal of Cancer*, **2009**, 125, 2342-8	7.5	66
67	Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer. *Nature Genetics*, **2009**, 41, 991-5	36.3	270
66	Pharmacogenomics of platinum-based chemotherapy in NSCLC. *Expert Opinion on Drug Metabolism and Toxicology*, **2009**, 5, 745-55	5.5	51

65	Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. *Nature Genetics*, **2008**, 40, 616-22	36.3	1036
64	Epidemiology and genetic susceptibility to bladder cancer. *BJU International*, **2008**, 102, 1207-15	5.6	56
63	Modulation of DNA damage/DNA repair capacity by XPC polymorphisms. *DNA Repair*, **2008**, 7, 141-8	4.3	64
62	Profiling of genetic variations in inflammation pathway genes in relation to bladder cancer predisposition. *Clinical Cancer Research*, **2008**, 14, 2236-44	12.9	44
61	Expression of methylation-related genes is associated with overall survival in patients with non-small cell lung cancer. *British Journal of Cancer*, **2008**, 98, 1716-22	8.7	36
60	Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. *Clinical Cancer Research*, **2008**, 14, 7956-62	12.9	197
59	Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. *Journal of the National Cancer Institute*, **2008**, 100, 1104-12	9.7	206
58	Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. *Cancer Prevention Research*, **2008**, 1, 460-9	3.2	178
57	Benzo(a)pyrene diol epoxide-induced chromosome 9p21 aberrations are associated with increased risk of bladder cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 2445-50	4	12
56	Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. *Pharmacogenetics and Genomics*, **2008**, 18, 955-65	1.9	40
55	Genetic susceptibility to bladder cancer with an emphasis on gene-gene and gene-environmental interactions. *Current Opinion in Urology*, **2008**, 18, 493-8	2.8	21
54	Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. *Cancer*, **2008**, 112, 2467-74	6.4	45
53	Prognostic significance of ataxia-telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer. *Cancer*, **2008**, 112, 2756-64	6.4	53
52	Pharmacogenetics in Cancer Chemotherapy **2008**, 113-128		1
51	Strategies to Identify Pharmacogenomic Biomarkers: Candidate Gene, Pathway-Based, and Genome-Wide Approaches **2008**, 353-370		2
50	Irradiation-induced telomerase activity and the risk of lung cancer: a pilot case-control study. *Cancer*, **2007**, 109, 1157-63	6.4	2
49	STK15 F31I polymorphism is associated with increased uterine cancer risk: a pilot study. *Gynecologic Oncology*, **2007**, 107, 71-4	4.9	20
48	Moving toward individualized therapy based on NER polymorphisms that predict platinum sensitivity in ovarian cancer patients. *Gynecologic Oncology*, **2007**, 107, S223-9	4.9	31

47	Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians. *Carcinogenesis*, **2007**, 28, 350-5	4.6	34
46	Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. *Clinical Cancer Research*, **2007**, 13, 2614-20	12.9	52
45	Mutagen sensitivity and genetic variants in nucleotide excision repair pathway: genotype-phenotype correlation. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 2065-71	4	41
44	Mutagen sensitivity: a genetic predisposition factor for cancer. *Cancer Research*, **2007**, 67, 3493-5	10.1	64
43	High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. *Carcinogenesis*, **2007**, 28, 2160-5	4.6	61
42	Projecting individualized probabilities of developing bladder cancer in white individuals. *Journal of Clinical Oncology*, **2007**, 25, 4974-81	2.2	63
41	Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. *Cancer Research*, **2007**, 67, 6520-7	10.1	116
40	Genetic polymorphism in bladder cancer. *Frontiers in Bioscience - Landmark*, **2007**, 12, 192-213	2.8	24
39	A nonsynonymous single-nucleotide polymorphism in the PDZ-Rho guanine nucleotide exchange factor (Ser1416Gly) modulates the risk of lung cancer in Mexican Americans. *Cancer*, **2006**, 106, 2716-24	6.4	55
38	Matrix metalloproteinase polymorphisms and bladder cancer risk. *Cancer Research*, **2006**, 66, 11644-8	10.1	61
37	Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions. *Carcinogenesis*, **2006**, 27, 2034-7	4.6	41
36	Mutagen sensitivity has high heritability: evidence from a twin study. *Cancer Research*, **2006**, 66, 5993-6	10.1	68
35	Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. *Journal of Clinical Oncology*, **2006**, 24, 3789-98	2.2	153
34	Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. *Clinical Cancer Research*, **2006**, 12, 7329-38	12.9	62
33	Joint effect of mutagen sensitivity and insulin-like growth factors in predicting the risk of developing secondary primary tumors and tumor recurrence in patients with head and neck cancer. *Clinical Cancer Research*, **2006**, 12, 7194-201	12.9	16
32	Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer. *Clinical Cancer Research*, **2006**, 12, 5720-5	12.9	46
31	Combined effects of the p53 and p73 polymorphisms on lung cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2006**, 15, 158-61	4	41
30	Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. *American Journal of Human Genetics*, **2006**, 78, 464-79	11	234

29	Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians. *Mutation Research - Genetic Toxicology and Environmental Mutagenesis*, **2005**, 581, 97-104	3	83
28	The pharmacogenetic impact of inflammatory genes on bladder cancer recurrence. *Pharmacogenomics*, **2005**, 6, 575-84	2.6	14
27	Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer. *Clinical Cancer Research*, **2005**, 11, 1408-15	12.9	83
26	Roles of tumor suppressor and telomere maintenance genes in cancer and aging--an epidemiological study. *Carcinogenesis*, **2005**, 26, 1741-7	4.6	20
25	Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. *Journal of Clinical Oncology*, **2005**, 23, 5746-56	2.2	123
24	Induction of apoptosis and down-regulation of Bcl-XL in cancer cells by a novel small molecule, 2[[3-(2,3-dichlorophenoxy)propyl]amino]ethanol. *Cancer Research*, **2004**, 64, 1110-3	10.1	30
23	Induction of p53-regulated genes in lung cancer cells: implications of the mechanism for adenoviral p53-mediated apoptosis. *Oncogene*, **2004**, 23, 1300-7	9.2	24
22	Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. *Molecular Therapy*, **2003**, 8, 441-8	11.7	55
21	Telomerase Promoter-Driven Cancer Cell Suicide. *Cancer Biology and Therapy*, **2003**, 2, 63-69	4.6	22
20	Cell to cell contact required for bystander effect of the TNF-related apoptosis-inducing ligand (TRAIL) gene **2003**, 22, 1241		3
19	Enhancing adenovirus-mediated gene transfer in vitro and in vivo by addition of protamine and hydrocortisone. *Journal of Gene Medicine*, **2003**, 5, 868-875	3.5	18
18	Telomerase promoter-driven cancer gene therapy. *Cancer Biology and Therapy*, **2003**, 2, S64-70	4.6	21
17	Mechanisms involved in development of resistance to adenovirus-mediated proapoptotic gene therapy in DLD1 human colon cancer cell line. *Gene Therapy*, **2002**, 9, 1262-70	4	43
16	Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. *Gene Therapy*, **2002**, 9, 1379-86	4	41
15	A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo. *Oncogene*, **2002**, 21, 4757-64	9.2	50
14	Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells. *Gynecologic Oncology*, **2002**, 85, 451-8	4.9	15
13	hTERT promoter induces tumor-specific Bax gene expression and cell killing in syngenic mouse tumor model and prevents systemic toxicity. *Gene Therapy*, **2002**, 9, 30-7	4	76
12	Bax-induction gene therapy of pancreatic cancer. *Journal of Surgical Research*, **2002**, 106, 346-51	2.5	30

11	Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. *Oncogene*, **2002**, 21, 8020-8	9.2	112
10	Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. *Cancer Research*, **2002**, 62, 3620-5	10.1	68
9	Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. *Molecular Therapy*, **2001**, 3, 278-83	11.7	42
8	Evolutionary conservation of post-transcriptional 3Tend adenylation of small RNAs: S. cerevisiae signal recognition particle RNA and U2 small nuclear RNA are post-transcriptionally adenylated. *Molecular and Cellular Biochemistry*, **2000**, 208, 99-109	4.2	10
7	Isolation and characterization of a new 110 kDa human nuclear RNA-binding protein (p110nrb). *Biochimica Et Biophysica Acta Gene Regulatory Mechanisms*, **1998**, 1399, 1-9		14
6	Adenylation of small RNAs in human cells. Development of a cell-free system for accurate adenylation on the 3Ŧend of human signal recognition particle RNA. *Journal of Biological Chemistry*, **1998**, 273, 6853-9	5.4	35
5	Small RNA database. *Nucleic Acids Research*, **1998**, 26, 160-2	20.1	16
4	Accurate 3Tend processing and adenylation of human signal recognition particle RNA and alu RNA in vitro. *Journal of Biological Chemistry*, **1998**, 273, 35023-31	5.4	31
3	Formation of 2Ţ3Ŧcyclic phosphates at the 3Tend of human U6 small nuclear RNA in vitro. Identification of 2Ţ3Ŧcyclic phosphates at the 3Tends of human signal recognition particle and mitochondrial RNA processing RNAs. *Journal of Biological Chemistry*, **1997**, 272, 21989-93	5.4	31
2	Small RNA database. *Nucleic Acids Research*, **1996**, 24, 73-5	20.1	6
1	Compilation of small RNA sequences. *Nucleic Acids Research*, **1994**, 22, 3481-2	20.1	9